Roquefort Therapeutics plc (LON:ROQ) experienced a 3.2% rise in its stock value on Thursday. The shares reached a high of GBX 0.98 and concluded trading at the same price. A total of approximately 439,612 shares changed hands, marking a notable decline of 54% compared to the average daily trading volume of 953,795 shares. The stock had closed the previous session at GBX 0.95.
The company currently holds a ratio of 2.80 for its current assets, while its quick ratio stands at 3.07. Additionally, Roquefort Therapeutics has a debt-to-equity ratio of 8.07. The 50-day simple moving average for the stock is recorded at GBX 1.19, with a 200-day simple moving average of GBX 1.55. The market capitalisation of Roquefort Therapeutics is estimated at £1.60 million, with a price-to-earnings ratio of -1.55 and a beta of 0.05.
Roquefort Therapeutics is listed on the LSE Main Market and operates within the biotechnology sector, focusing on the development of first-in-class drugs in the high-value and rapidly growing oncology market. The company aims to partner with or sell its innovations to larger pharmaceutical corporations. Since its listing in March 2021, Roquefort Therapeutics has successfully acquired Lyramid Pty Limited, a leader in developing medicines targeting Midkine, a human growth factor linked to cancer progression. Furthermore, it has recently acquired Oncogeni Ltd, an enterprise founded by Nobel Laureate Professor Sir Martin Evans, which has pioneered two families of innovative cell and RNA oncology medicines.